In this article, we will look at the 5 Stocks Dominating Today’s Market Surge. For a deeper discussion and an extended list, please see 10 Stocks Dominating Today’s Market Surge.

5. Uniti Group Inc. (NASDAQ:UNIT)

Uniti extended its rally for a third straight day on Tuesday, jumping 15.80 percent to finish at $9.38 apiece, as investor sentiment was bolstered by reports that two technology giants are setting their sights on buying its assets.

According to a report by TMT Finance, T-Mobile US and TPG are looking into acquiring Uniti Group Inc.’s (NASDAQ:UNIT) assets, with the former said to be interested in the kinetic fiber-to-the-home business, while the latter is eyeing the enterprise side.

Another source privy to the matter said that the two could also partner for an offer of full acquisition of the company.

Uniti Group Inc. (NASDAQ:UNIT) has yet to kick off a formal sale process, although it was said to be open to reviewing interests from several parties.

Sale aside, the rally also mirrored an overall market optimism, with Wall Street’s three major indices soaring by 2 to 3 percent during the day.

In other news, Uniti Group Inc. (NASDAQ:UNIT) welcomed on Monday Heather Orrico as president for Enterprise Sales. As the leader of the said segment, she is tasked to guide the enterprise sales approach and support growth efforts across the southeast region of the country.

Orrico boasts of more than 20 years of experience in the telecommunications sector, across engineering, operations, and sales.

4. Alkermes PLC (NASDAQ:ALKS)

Alkermes extended gains for a second day on Tuesday to nearly hit its 52-week high, as investors digested the growing interest in the orexin receptor agonist market following a pharmaceutical giant’s official foray into the sector.

Weight loss drugmaker Eli Lilly and Company announced on the same day that it entered into a definitive agreement to acquire Centessa Pharmaceuticals—a clinical-stage company currently developing a pipeline of orexin receptor 2—for $6.3 billion.

The positive sentiment spilled over to Alkermes PLC (NASDAQ:ALKS), as Eli Lilly’s acquisition suggested a strong demand for the market.

Alkermes PLC (NASDAQ:ALKS) is likewise developing its own orexin 2 receptor agonists for other neurological disorders, including ADHD and fatigue associated with multiple sclerosis and Parkinson’s disease.

On the same day, its stock surged to a day high of $36.22, or just 10 cents shy of its 52-week high of $36.32, before paring gains to end the session just up by 17.28 percent at $35.36 apiece.

Last year, Alkermes PLC (NASDAQ:ALKS) saw its net income decline by 34 percent to $241.7 million from $367.1 million in 2024, while revenues dropped by 5 percent to $1.47 billion from $1.5 billion.

In the fourth quarter alone, net profit fell by 66 percent to $49.3 million from $146.5 million, while revenues decreased by 10.6 percent to $384.5 million from $430 million.

3. Firefly Aerospace Inc. (NASDAQ:FLY)

Firefly Aerospace snapped a three-day losing streak on Tuesday, soaring 20.53 percent to finish at $28.47 apiece, riding the optimistic sentiment ahead of SpaceX’s initial public offering (IPO).

A report by Reuters on Tuesday said that the Elon Musk-led company has lined up 21 banks for its mega IPO, potentially valuing the company at $1.75 trillion.

SpaceX is attempting to raise more than $75 billion in what could be one of the largest IPOs in history.

In other news, Firefly Aerospace Inc. (NASDAQ:FLY) earlier this month announced mixed earnings performance last year, having widened its net losses but markedly expanded its revenues.

According to the company, net loss attributable to shareholders last year increased by 25.6 percent to $333.96 million from $265.81 million in 2024. Revenues, on the other hand, soared by 163 percent to $159.8 million from $60.79 million.

In the fourth quarter alone, net loss attributable to shareholders narrowed by 60 percent to $41 million from $102.9 million, while revenues soared by 541 percent to $57.67 million from $9.03 million.

2. Centessa Pharmaceuticals PLC (NASDAQ:CNTA)

Centessa soared to a new all-time high on Tuesday, as investors gobbled up shares following news that it is set to be acquired by giant weight loss drugmaker Eli Lilly and Company, for $6.3 billion.

In a statement, Eli Lilly said that it entered into a definitive agreement with Centessa Pharmaceuticals PLC (NASDAQ:CNTA) for the acquisition of its shares at a price of $38, or a 38 percent upside from its closing price of $27.58 prior to the announcement.

In addition, shareholders of Centessa Pharmaceuticals PLC (NASDAQ:CNTA) are set to receive $9 upon the achievement of three milestones, including $2 upon FDA approval of cleminorexton for narcolepsy type 2; $5 upon its FDA approval for the treatment of idiopathic hypersomnia; and $2 for its treatment of any indication prior to January 1, 2030. Payments of the contingent value right are not guaranteed.

The transaction is expected to be completed in the third quarter of the year, subject to closing conditions, including regulatory approvals.

“We are thrilled to take our next step toward a potential combination with Lilly, which shares our vision. By combining Centessa’s team and capabilities with Lilly’s global complementary research, clinical, regulatory, and commercial capabilities, we will seek to accelerate the advancement of our orexin portfolio across a broad range of neuroscience indications for the benefit of patients in need,” Centessa Pharmaceuticals PLC (NASDAQ:CNTA) CEO Mario Alberto Accardi said.

1. Apellis Pharmaceuticals Inc. (NASDAQ:APLS)

Apellis Pharmaceuticals climbed to a new two-year high on Tuesday, as investors gobbled up shares following news that it was set to be acquired by Biogen Inc. at a 140-percent upside.

In intra-day trading, the stock soared to its highest price of $40.45 before trimming a few cents to finish the day just up by 135.40 percent at $40.23 apiece.

In a statement, Apellis Pharmaceuticals Inc. (NASDAQ:APLS) said that it entered into a definitive agreement with Biogen for the latter’s acquisition of its shares at a price of $41 apiece, for a total of $5.6 billion.

On top of the acquisition price, shareholders would likewise receive $2 in cash for every share held, contingent on the achievement of certain annual global sales for Syfovre.

“This transaction represents a compelling outcome for our shareholders and a strong validation of our strategy, scientific innovation, and execution,” Apellis Pharmaceuticals Inc. (NASDAQ:APLS) CEO Cedric Francois said.

“With Biogen’s extensive experience with immunology and rare disease, we believe this transaction will accelerate our impact and enable us to reach more patients,” he added.

The transaction is expected to be closed in the second quarter of the year, subject to customary closing conditions, including regulatory approvals. It is expected to add immediate sales revenue to Biogen, with Apellis Pharmaceuticals Inc.’s (NASDAQ:APLS) Syfovre and Empaveli having achieved combined net sales of $689 million in 2025.

READ NEXT: 33 Stocks That Should Double in 3 Years and 15 Stocks That Will Make You Rich in 10 Years.

Disclosure: None. Insider Monkey focuses on uncovering the best investment ideas of hedge funds and insiders. Please subscribe to our free daily e-newsletter to get the latest investment ideas from hedge fund investor letters by entering your email below.